MTOR Inhibition and Cardiovascular Diseases: Dyslipidemia and Atherosclerosis. (February 2018)

• Record Type: Journal Article
• Authors: Kurdi, Ammar; Martinet, Wim; De Meyer, Guido R.Y.
• Is Part Of: Transplantation. Volume 102(2018)Supplement 1 2S
• Publication Date: 2018-02
• Subjects: Transplantation of organs, tissues, etc -- Periodicals; Transplantation immunology -- Periodicals; 617.95
• DOI: 10.1097/TP.0000000000001693
• Languages: English
• ISSNs: 0041-1337

Abstract

Abstract : Abstract: Inhibitors of the mechanistic target of rapamycin (mTOR) have unique antiatherosclerotic effects, such as depletion of plaque macrophages, induction of autophagy, and activation of cholesterol efflux. However, a common side effect of their use is dyslipidemia, a well-known risk factor for atherosclerosis. Indeed, mTOR inhibitors prevent lipid storage, increase low-density lipoprotein cholesterol levels, and activate lipolysis. Although the net effect of mTOR inhibition seems favorable, the use of cholesterol lowering drugs to manage dyslipidemia remains the most recommended strategy.